Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.

The oncologist - 1 Sept 2014

Vornicova Olga, Hershkovitz Dov, Yablonski-Peretz Tamar, Ben-Itzhak Ofer, Keidar Zohar, Bar-Sela Gil

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cancer and Skin Lesions
Share to ERBB2 gene
Share to Genome, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Metastasis

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 25085898
DOI: 10.1634/theoncologist.2014-0054
PMCID: PMC4153459

Genes

ERBB2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.PMID 25085898Read ↗

Identification of potentially druggable molecular alterations in skin adnexal malignanciesSemantic proximity Read ↗

Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.Semantic proximity Read ↗

Treatment with Antitumor Agents Recommended by Cancer Genome Panel for Uterine LeiomyosarcomaSemantic proximity Read ↗

CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspectiveSemantic proximity Read ↗

Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis.Semantic proximity Read ↗

Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the VulvaSemantic proximity Read ↗

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read ↗

Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma.Semantic proximity Read ↗

Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens.Semantic proximity Read ↗

Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.Semantic proximity Read ↗

Poziotinib for uncommon ERBB mutations.Semantic proximity Read ↗

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.